Merck opts to develop, sell cancer vaccine with Moderna

[October 13, 2022]  (Reuters) -Merck & Co Inc opted to jointly develop and potentially sell a personalized mRNA vaccine with Moderna Inc for a $250 million upfront payment on Wednesday, sending the vaccine maker's shares up over 8%.

Moderna's experimental vaccine is being tested in combination with Merck's blockbuster cancer immunotherapy, Keytruda, in a mid-stage trial to treat patients with melanoma. Data on the vaccine, mRNA-4157, is expected in the fourth quarter of this year.

With the size of the COVID-19 vaccine market expected to contract in subsequent years from the levels seen in 2021, Moderna has been pinning its hopes on its non-COVID vaccines which includes influenza and respiratory syncytial virus shots.

The cancer vaccine is tailored for each patient to generate T-cells, a key part of the body's immune response, based on the specific mutational signature of a tumor.

 Moderna's logo is reflected in a drop on a syringe needle in this illustration taken November 9, 2020. REUTERS/Dado Ruvic/Illustration/File Photo

In 2016, Merck and Moderna entered a strategic partnership to develop a personalized vaccine for treatment of various types of cancer.

Merck in 2020 sold its equity investment in Moderna, benefiting from a surge in the vaccine-maker's stock price that year.

(Reporting by Manas Mishra and Khushi Mandowara in Bengaluru; Editing by Shinjini Ganguli)

[© 2022 Thomson Reuters. All rights reserved.] 

This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.